| Literature DB >> 27518527 |
Vijay M Ravindra1, Amol Raheja1, Heather Corn2, Meghan Driscoll3, Corrine Welt2, Debra L Simmons2, William T Couldwell1.
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma and comprises approximately 30% of all lymphomas. Patients typically present with a nonpainful mass in the neck, groin, or abdomen associated with constitutional symptoms. In this report, however, the authors describe a rare case of a 61-year-old woman with hyperprolactinemia, hypothyroidism, and acromegaly (elevation of insulin-like growth factor-1 [IGF-1]) with elevated growth hormone-releasing hormone (GHRH) in whom an MRI demonstrated diffuse enlargement of the pituitary gland. Despite medical treatment, the patient had persistent elevation of IGF-1. She underwent a transsphenoidal biopsy, which yielded a diagnosis of DLBCL with an activated B-cell immunophenotype with somatotroph hyperplasia. After stereo-tactic radiation therapy in combination with chemotherapy, she is currently in remission from her lymphoma and has normalized IGF-1 levels without medical therapy, 8 months after her histopathological diagnosis. This is the only reported case of its kind and displays the importance of a broad differential diagnosis, multidisciplinary evaluation, and critical intraoperative decision-making when treating atypical sellar lesions.Entities:
Keywords: ACTH = adrenocorticotropic hormone; B-cell; DLBCL = diffuse large B-cell lymphoma; GHRH = growth hormone–releasing hormone; IGF-1 = insulin-like growth factor-1; NHL = non-Hodgkin lymphoma; PCNSL = primary central nervous system lymphoma; R-CHOP = rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine sulfate, and prednisone; SIADH = syndrome of inappropriate antidiuretic hormone; TSH = thyroid-stimulating hormone; lymphoma; pituitary surgery; somatotroph hyperplasia
Mesh:
Year: 2016 PMID: 27518527 DOI: 10.3171/2016.5.JNS16828
Source DB: PubMed Journal: J Neurosurg ISSN: 0022-3085 Impact factor: 5.115